vs
AvePoint（AVPT）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
AvePoint的季度营收约是RIGEL PHARMACEUTICALS INC的1.6倍（$114.7M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 13.6%，领先370.4%），AvePoint同比增速更快（28.6% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 24.0%）
AvePoint是一家总部位于美国新泽西州泽西市的企业，成立于2001年，2020年在纳斯达克上市。公司专注于开发软件产品，为Microsoft 365、谷歌、Salesforce等主流平台提供功能拓展与安全增强解决方案，服务全球各行业客户的数字化协作与数据治理需求。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
AVPT vs RIGL — 直观对比
营收规模更大
AVPT
是对方的1.6倍
$69.8M
营收增速更快
AVPT
高出7.4%
21.2%
净利率更高
RIGL
高出370.4%
13.6%
两年增速更快
RIGL
近两年复合增速
24.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.7M | $69.8M |
| 净利润 | $15.6M | $268.1M |
| 毛利率 | 73.6% | 91.5% |
| 营业利润率 | 12.7% | 33.2% |
| 净利率 | 13.6% | 384.0% |
| 营收同比 | 28.6% | 21.2% |
| 净利润同比 | 191.1% | 1769.2% |
| 每股收益（稀释后） | $0.06 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVPTRIGL
| Q4 25 | $114.7M | $69.8M | ||
| Q3 25 | $109.7M | $69.5M | ||
| Q2 25 | $102.0M | $101.7M | ||
| Q1 25 | $93.1M | $53.3M | ||
| Q4 24 | $89.2M | $57.6M | ||
| Q3 24 | $88.8M | $55.3M | ||
| Q2 24 | $78.0M | $36.8M | ||
| Q1 24 | $74.5M | $29.5M |
净利润AVPTRIGL
| Q4 25 | $15.6M | $268.1M | ||
| Q3 25 | $13.0M | $27.9M | ||
| Q2 25 | $2.9M | $59.6M | ||
| Q1 25 | $3.6M | $11.4M | ||
| Q4 24 | $-17.2M | $14.3M | ||
| Q3 24 | $2.6M | $12.4M | ||
| Q2 24 | $-12.9M | $-1.0M | ||
| Q1 24 | $-2.0M | $-8.2M |
毛利率AVPTRIGL
| Q4 25 | 73.6% | 91.5% | ||
| Q3 25 | 74.4% | 93.2% | ||
| Q2 25 | 74.0% | 95.6% | ||
| Q1 25 | 74.3% | 91.7% | ||
| Q4 24 | 75.4% | 89.9% | ||
| Q3 24 | 76.1% | 85.5% | ||
| Q2 24 | 75.7% | 92.4% | ||
| Q1 24 | 72.6% | 93.1% |
营业利润率AVPTRIGL
| Q4 25 | 12.7% | 33.2% | ||
| Q3 25 | 7.4% | 40.9% | ||
| Q2 25 | 7.0% | 60.1% | ||
| Q1 25 | 3.5% | 23.9% | ||
| Q4 24 | 5.4% | 28.9% | ||
| Q3 24 | 8.6% | 25.4% | ||
| Q2 24 | -2.7% | 1.2% | ||
| Q1 24 | -4.3% | -23.6% |
净利率AVPTRIGL
| Q4 25 | 13.6% | 384.0% | ||
| Q3 25 | 11.9% | 40.2% | ||
| Q2 25 | 2.8% | 58.6% | ||
| Q1 25 | 3.8% | 21.5% | ||
| Q4 24 | -19.3% | 24.9% | ||
| Q3 24 | 3.0% | 22.5% | ||
| Q2 24 | -16.6% | -2.8% | ||
| Q1 24 | -2.6% | -27.9% |
每股收益（稀释后）AVPTRIGL
| Q4 25 | $0.06 | $14.11 | ||
| Q3 25 | $0.06 | $1.46 | ||
| Q2 25 | $0.01 | $3.28 | ||
| Q1 25 | $0.02 | $0.63 | ||
| Q4 24 | $-0.09 | $0.82 | ||
| Q3 24 | $0.01 | $0.70 | ||
| Q2 24 | $-0.07 | $-0.06 | ||
| Q1 24 | $-0.01 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $481.1M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $478.7M | $391.5M |
| 总资产 | $789.2M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资AVPTRIGL
| Q4 25 | $481.1M | $155.0M | ||
| Q3 25 | $471.6M | $137.1M | ||
| Q2 25 | $430.1M | $108.4M | ||
| Q1 25 | $351.8M | $77.1M | ||
| Q4 24 | $290.9M | $77.3M | ||
| Q3 24 | $250.0M | $61.1M | ||
| Q2 24 | $230.8M | $49.1M | ||
| Q1 24 | $219.3M | $49.5M |
总债务AVPTRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益AVPTRIGL
| Q4 25 | $478.7M | $391.5M | ||
| Q3 25 | $466.8M | $117.6M | ||
| Q2 25 | $443.1M | $81.9M | ||
| Q1 25 | $361.5M | $18.6M | ||
| Q4 24 | $270.9M | $3.3M | ||
| Q3 24 | $215.7M | $-14.6M | ||
| Q2 24 | $207.4M | $-29.9M | ||
| Q1 24 | $212.7M | $-31.7M |
总资产AVPTRIGL
| Q4 25 | $789.2M | $513.6M | ||
| Q3 25 | $743.5M | $242.5M | ||
| Q2 25 | $700.1M | $206.7M | ||
| Q1 25 | $598.8M | $176.0M | ||
| Q4 24 | $519.1M | $164.0M | ||
| Q3 24 | $463.0M | $139.4M | ||
| Q2 24 | $427.3M | $128.4M | ||
| Q1 24 | $413.8M | $126.5M |
负债/权益比AVPTRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.7M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $29.0M | — |
| 自由现金流率自由现金流/营收 | 25.3% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.90× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $81.6M | — |
8季度趋势，按日历期对齐
经营现金流AVPTRIGL
| Q4 25 | $29.7M | $22.0M | ||
| Q3 25 | $34.8M | $24.0M | ||
| Q2 25 | $20.3M | $30.5M | ||
| Q1 25 | $495.0K | $-893.0K | ||
| Q4 24 | $32.8M | $14.5M | ||
| Q3 24 | $32.2M | $21.7M | ||
| Q2 24 | $16.2M | $302.0K | ||
| Q1 24 | $7.8M | $-5.0M |
自由现金流AVPTRIGL
| Q4 25 | $29.0M | — | ||
| Q3 25 | $34.3M | — | ||
| Q2 25 | $19.3M | — | ||
| Q1 25 | $-1.0M | — | ||
| Q4 24 | $32.0M | — | ||
| Q3 24 | $30.8M | — | ||
| Q2 24 | $15.8M | — | ||
| Q1 24 | $7.3M | — |
自由现金流率AVPTRIGL
| Q4 25 | 25.3% | — | ||
| Q3 25 | 31.3% | — | ||
| Q2 25 | 18.9% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 34.7% | — | ||
| Q2 24 | 20.2% | — | ||
| Q1 24 | 9.7% | — |
资本支出强度AVPTRIGL
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.7% | — |
现金转化率AVPTRIGL
| Q4 25 | 1.90× | 0.08× | ||
| Q3 25 | 2.68× | 0.86× | ||
| Q2 25 | 7.01× | 0.51× | ||
| Q1 25 | 0.14× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 12.30× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVPT
| SAAS | $88.9M | 78% |
| Services | $14.7M | 13% |
| Termed License And Support | $10.1M | 9% |
RIGL
暂无分部数据
